FrontAim Biomedicines

FrontAim Biomedicines is a pre-clinical stage biotechnology company focused on developing next-generation multispecific antibody therapeutics and antibody-drug conjugates (ADCs) for intractable cancers, including triple-negative breast cancer, small cell lung cancer, and hematological malignancies. The company's proprietary technology suite includes the intracellular molecular grafting (MG) platform and the MG-Ig bispecific 2.0 platform, which enable the efficient, single-host cell production of trivalent, IgG-like bispecific antibodies that retain natural homodimeric Fc structures. FrontAim is also advancing next-generation ADCs (NG-ADCs), including superior Trop-2-targeted ADCs designed for enhanced efficacy, safety, and manufacturability. Headquartered in Princeton, New Jersey, the company was founded by former Immunomedics scientists and has secured seed funding from investors such as Sangel Capital.